Effects of supplementation with quercetin on plasma C-reactive protein concentrations: a systematic review and meta-analysis of randomized controlled trials
Mohammadi-Sartang, M
(Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran)
,
Mazloom, Z
(Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran)
,
Sherafatmanesh, S
(Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran)
,
Ghorbani, M
(Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran)
,
Firoozi, Donya
(Department of Clinical Nutrition, School of Nutrition and Food Sciences, Shiraz University of Medical Sciences, Shiraz, Iran)
Promising experimental studies suggest that quercetin has potential anti-inflammatory effects. However, the results of current clinical trials on quercetin’s effects on the C-reactive protein (CRP), a sensitive inflammatory biomarker, are ambiguous. We conducted a meta-analysis of available ra...
Promising experimental studies suggest that quercetin has potential anti-inflammatory effects. However, the results of current clinical trials on quercetin’s effects on the C-reactive protein (CRP), a sensitive inflammatory biomarker, are ambiguous. We conducted a meta-analysis of available randomized controlled trials (RCTs) to resolve this inconsistency and quantify the net effect of quercetin on circulating CRP concentrations. A systematic search was performed in several databases including SCOPUS, PubMed–Medline and Google Scholar until 16 June 2016. We used a random-effects model in combination with weight mean difference (WMD) and 95% confidence intervals (CI) for data analysis. Standard methods were used for the assessment of heterogeneity, meta-regression, sensitivity analysis and publication bias. The meta-analysis of seven RCTs (10 treatment arms) showed a significant reduction of circulating CRP levels (WMD: −0.33 mg/l; 95% CI: −0.50 to −0.15; P<0.001) following quercetin supplementation. In the subgroup analysis, a significant reducing effect was observed in trials with ⩾500 mg/day dosage (WMD: −0.34 mg/l; 95% CI: −0.52, −0.16; P⩽0.001) and in those with CRP <3 mg/l (WMD: −0.34 mg/l; 95% CI: −0.51, −0.18; P⩽0.001). In meta-regression, there was no association between changes in CRP concentrations, dose of supplementation and CRP baseline values. Our findings showed a significant effect of quercetin supplementation on the C-reactive protein—especially at doses above 500 mg/day and in patients with CRP <3 mg/l.
Promising experimental studies suggest that quercetin has potential anti-inflammatory effects. However, the results of current clinical trials on quercetin’s effects on the C-reactive protein (CRP), a sensitive inflammatory biomarker, are ambiguous. We conducted a meta-analysis of available randomized controlled trials (RCTs) to resolve this inconsistency and quantify the net effect of quercetin on circulating CRP concentrations. A systematic search was performed in several databases including SCOPUS, PubMed–Medline and Google Scholar until 16 June 2016. We used a random-effects model in combination with weight mean difference (WMD) and 95% confidence intervals (CI) for data analysis. Standard methods were used for the assessment of heterogeneity, meta-regression, sensitivity analysis and publication bias. The meta-analysis of seven RCTs (10 treatment arms) showed a significant reduction of circulating CRP levels (WMD: −0.33 mg/l; 95% CI: −0.50 to −0.15; P<0.001) following quercetin supplementation. In the subgroup analysis, a significant reducing effect was observed in trials with ⩾500 mg/day dosage (WMD: −0.34 mg/l; 95% CI: −0.52, −0.16; P⩽0.001) and in those with CRP <3 mg/l (WMD: −0.34 mg/l; 95% CI: −0.51, −0.18; P⩽0.001). In meta-regression, there was no association between changes in CRP concentrations, dose of supplementation and CRP baseline values. Our findings showed a significant effect of quercetin supplementation on the C-reactive protein—especially at doses above 500 mg/day and in patients with CRP <3 mg/l.
참고문헌 (42)
BMJ P Knekt 312 478 1996 10.1136/bmj.312.7029.478 Knekt P, Jarvinen R, Reunanen A, Maatela J . Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 1996; 312: 478-481.
Front Plant Sci MLF Ferreyra 3 222 2012 Ferreyra MLF, Rius SP, Casati P . Flavonoids: biosynthesis, biological functions, and biotechnological applications. Front Plant Sci 2012; 3: 222.
Nutr Res I Erlund 24 851 2004 10.1016/j.nutres.2004.07.005 Erlund I . Review of the flavonoids quercetin, hesperetin, and naringenin. Dietary sources, bioactivities, bioavailability, and epidemiology. Nutr Res 2004; 24: 851-874.
Curr Top Med Chem J Guillermo Gormaz 15 1735 2015 10.2174/1568026615666150427124357 Guillermo Gormaz J, Quintremil S, Rodrigo R . Cardiovascular disease: a target for the pharmacological effects of quercetin. Curr Top Med Chem 2015; 15: 1735-1742.
Atherosclerosis R Kleemann 218 44 2011 10.1016/j.atherosclerosis.2011.04.023 Kleemann R, Verschuren L, Morrison M, Zadelaar S, van Erk MJ, Wielinga PY et al. Anti-inflammatory, anti-proliferative and anti-atherosclerotic effects of quercetin in human in vitro and in vivo models. Atherosclerosis 2011; 218: 44-52.
Internet J Med Update P Lakhanpal 2 22 2007 Lakhanpal P, Rai DK . Quercetin: a versatile flavonoid. Internet J Med Update 2007; 2: 22-37.
J Nutr M Sanchez 137 910 2007 10.1093/jn/137.4.910 Sanchez M, Lodi F, Vera R, Villar IC, Cogolludo A, Jimenez R et al. Quercetin and isorhamnetin prevent endothelial dysfunction, superoxide production, and overexpression of p47phox induced by angiotensin II in rat aorta. J Nutr 2007; 137: 910-915.
J Thromb Haemost G Hubbard 1 1079 2003 10.1046/j.1538-7836.2003.00212.x Hubbard G, Stevens J, Cicmil M, Sage T, Jordan P, Williams C et al. Quercetin inhibits collagenstimulated platelet activation through inhibition of multiple components of the glycoprotein VI signaling pathway. J Thromb Haemost 2003; 1: 1079-1088.
Life Sci MM Alam 109 8 2014 10.1016/j.lfs.2014.06.005 Alam MM, Meerza D, Naseem I . Protective effect of quercetin on hyperglycemia, oxidative stress and DNA damage in alloxan induced type 2 diabetic mice. Life Sci 2014; 109: 8-14.
Food Chem SF Nabavi 179 305 2015 10.1016/j.foodchem.2015.02.006 Nabavi SF, Russo GL, Daglia M, Nabavi SM . Role of quercetin as an alternative for obesity treatment: you are what you eat!. Food Chem 2015; 179: 305-310.
Anti-Cancer Agents Med Chem K Men 14 826 2014 10.2174/1871520614666140521122932 Men K, Duan X, Wei X, Ling Gou M, Juan Huang M, Juan Chen L et al. Nanoparticle-delivered quercetin for cancer therapy. Anti-Cancer Agents Med Chem 2014; 14: 826-832.
Circulation V Pasceri 102 2165 2000 10.1161/01.CIR.102.18.2165 Pasceri V, Willerson JT, Yeh ET . Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168.
Food Funct N Das 4 889 2013 10.1039/c3fo30241e Das N, Sikder K, Bhattacharjee S, Majumdar SB, Ghosh S, Majumdar S et al. Quercetin alleviates inflammation after short-term treatment in high-fat-fed mice. Food Funct 2013; 4: 889-898.
J Res Med Sci G Askari 17 637 2012 Askari G, Ghiasvand R, Feizi A, Ghanadian SM, Karimian J . The effect of quercetin supplementation on selected markers of inflammation and oxidative stress. J Res Med Sci 2012; 17: 637-641.
J Nutr S Egert 140 278 2010 10.3945/jn.109.117655 Egert S, Boesch-Saadatmandi C, Wolffram S, Rimbach G, Muller MJ . Serum lipid and blood pressure responses to quercetin vary in overweight patients by apolipoprotein E genotype. J Nutr 2010; 140: 278-284.
Int J Prev Med F Javadi 5 293 2014 Javadi F, Eghtesadi S, Ahmadzadeh A, Aryaeian N, Zabihiyeganeh M, Foroushani AR et al. The effect of quercetin on plasma oxidative status, C-reactive protein and blood pressure in women with rheumatoid arthritis. Int J Prev Med 2014; 5: 293-301.
Int J Prev Med M Zahedi 4 777 2013 Zahedi M, Ghiasvand R, Feizi A, Asgari G, Darvish L . Does quercetin improve cardiovascular risk factors and inflammatory biomarkers in women with type 2 diabetes: a double-blind randomized controlled clinical trial. Int J Prev Med 2013; 4: 777-785.
J Nutr JI Dower 145 1459 2015 10.3945/jn.115.211888 Dower JI, Geleijnse JM, Gijsbers L, Schalkwijk C, Kromhout D, Hollman PC . Supplementation of the pure flavonoids epicatechin and quercetin affects some biomarkers of endothelial dysfunction and inflammation in (pre) hypertensive adults: a randomized double-blind, placebo-controlled, crossover trial. J Nutr 2015; 145: 1459-1463.
Health Technol Assess D Moher 3 1 1999 10.3310/hta3120 Moher D, Cook D, Jadad A, Tugwell P, Moher M, Jones A et al. Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess 1999; 3: 1-98. i.
M Borenstein 104 2005 Comprehensive Meta-Analysis Version 2 Borenstein M, Hedges L, Higgins J, Rothstein H . Comprehensive Meta-Analysis Version 2. Biostat: Englewood, NJ, 2005, pp 104.
Br J Nutr V Brull 114 1263 2015 10.1017/S0007114515002950 Brull V, Burak C, Stoffel-Wagner B, Wolffram S, Nickenig G, Muller C et al. Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial. Br J Nutr 2015; 114: 1263-1277.
Nutr Metab Cardiovasc Dis M Pfeuffer 23 403 2013 10.1016/j.numecd.2011.08.010 Pfeuffer M, Auinger A, Bley U, Kraus-Stojanowic I, Laue C, Winkler P et al. Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. Nutr Metab Cardiovasc Dis 2013; 23: 403-409.
Eur J Pharmacol V Garcia-Mediavilla 557 221 2007 10.1016/j.ejphar.2006.11.014 Garcia-Mediavilla V, Crespo I, Collado PS, Esteller A, Sanchez-Campos S, Tunon MJ et al. The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol 2007; 557: 221-229.
Int J Prev Med M Zahedi 4 777 2013 Zahedi M, Ghiasvand R, Feizi A, Asgari G, Darvishi L . Does quercetin improve cardiovascular risk factors and inflammatory biomarkers in women with type 2 diabetes: a double-blind randomized controlled clinical trial. Int J Prev Med 2013; 4: 777-785.
Nutrition AW Boots 24 703 2008 10.1016/j.nut.2008.03.023 Boots AW, Wilms LC, Swennen EL, Kleinjans JC, Bast A, Haenen GR . In vitro and ex vivo anti-inflammatory activity of quercetin in healthy volunteers. Nutrition 2008; 24: 703-710.
Obesity L Rivera 16 2081 2008 10.1038/oby.2008.315 Rivera L, Moron R, Sanchez M, Zarzuelo A, Galisteo M . Quercetin ameliorates metabolic syndrome and improves the inflammatory status in obese Zucker rats. Obesity 2008; 16: 2081-2087.
Biochem Pharmacol WM Loke 75 1045 2008 10.1016/j.bcp.2007.11.002 Loke WM, Proudfoot JM, Stewart S, McKinley AJ, Needs PW, Kroon PA et al. Metabolic transformation has a profound effect on anti-inflammatory activity of flavonoids such as quercetin: lack of association between antioxidant and lipoxygenase inhibitory activity. Biochem Pharmacol 2008; 75: 1045-1053.
Curr Pharm Des Y Kumazawa 12 4271 2006 10.2174/138161206778743565 Kumazawa Y, Kawaguchi K, Takimoto H . Immunomodulating effects of flavonoids on acute and chronic inflammatory responses caused by tumor necrosis factor alpha. Curr Pharm Des 2006; 12: 4271-4279.
Food Chem Toxicol M Harwood 45 2179 2007 10.1016/j.fct.2007.05.015 Harwood M, Danielewska-Nikiel B, Borzelleca J, Flamm G, Williams G, Lines T . A critical review of the data related to the safety of quercetin and lack of evidence of in vivo toxicity, including lack of genotoxic/carcinogenic properties. Food Chem Toxicol 2007; 45: 2179-2205.
J Am Pharmaceut Assoc AM Ambrose 41 119 1952 10.1002/jps.3030410303 Ambrose AM, Robbins DJ, Deeds F . Comparative toxicities of quercetin and quercitrin. J Am Pharmaceut Assoc 1952; 41: 119-122.
Teratog Carcinog Mutagen D Saito 1 213 1980 10.1002/tcm.1770010209 Saito D, Shirai A, Matsushima T, Sugimura T, Hirono I . Test of carcinogenicity of quercetin, a widely distributed mutagen in food. Teratog Carcinog Mutagen 1980; 1: 213-221.
Cancer Lett I Hirono 13 15 1981 10.1016/0304-3835(81)90081-1 Hirono I, Ueno I, Hosaka S, Takanashi H, Matsushima T, Sugimura T et al. Carcinogenicity examination of quercetin and rutin in ACI rats. Cancer Lett 1981; 13: 15-21.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.